Document is current
Any future updates will be listed below
-
Authors
Pruis, Melinda A. https://orcid.org/0000-0003-4361-0020
Groenendijk, Floris H.
Badloe, K. Sangeeta
van Puffelen, Andrea
Robbrecht, Debbie https://orcid.org/0000-0003-2490-9991
Dinjens, Winand N. M.
Sleijfer, Stefan
Dingemans, Anne-Marie C. https://orcid.org/0000-0001-6105-182X
von der Thüsen, Jan H. https://orcid.org/0000-0001-9699-4860
Roepman, Paul
Lolkema, Martijn P. https://orcid.org/0000-0003-0466-2928
- License Information
-
More Information
Article History
Received: 21 October 2021
Revised: 4 April 2022
Accepted: 4 May 2022
First Online: 23 May 2022
Competing interests
: A-MCD reports receiving research support from AstraZeneca, Bristol-Myers Squibb and Abbvie; receiving honoraria from Amgen, Bayer, Bristol-Myers Squibb, Novartis, Roche. A-MCD reports having honoraria from Eli Lily, AstraZeneca, Jansen, Chiesi, Pfizer and Takeda; receiving grants from Amgen; having participation on a data safety monitoring board or advisory board of Boehringer Ingelheim, Amgen, Bayer, Pharmamar and Sanofi; having leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid of Roche. JHvdT reports receiving grants from Bristol-Myers Squibb and AstraZeneca; consulting fees from Bristol-Myers Squibb, Eli Lily and Roche; honoraria from Johnson & Johnson and MSD; receiving medical equipment from Roche Diagnostics. MPL reports receiving grants from Janssen Cilag B.V., Sanofi and Merck; consulting fees from Pfizer, AstraZeneca, Astellas, Merck, Novartis, Julius Clinical and Stichting Treat Meds. The remaining authors declare no competing interests.
: Written informed consent was obtained from all patients for the data collection. This study was approved by our local Medical Ethical Committee (METC 19-0446), Erasmus Medical Center. The study was performed in accordance with the Declaration of Helsinki.
